Trump Administration Spends First Half Of Second Term Dismantling The Nation's Public Health Defenses, Resolving Long-Standing Concern That The Government Was Still Trying To Prevent Disease

The Filing

WASHINGTON. The Trump administration confirmed this week that 15 months of sustained action against the federal public health apparatus had achieved its central aim, ensuring that the United States government is no longer meaningfully organized around the prevention of disease.

The effort began on the first day of the term, when the President signed an executive order withdrawing the country from the World Health Organization, removing the United States from the body that coordinates the international response to outbreaks. Within weeks the Senate confirmed Robert F. Kennedy Jr. as Secretary of Health and Human Services, after which the administration began purging the federal vaccine advisory structure and replacing its members with figures who had built careers questioning vaccines. Officials described the changes as a restoration of common sense rather than the removal of expertise.

In March the administration laid off roughly 20,000 employees across HHS, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health, then halted several CDC infectious disease tracking programs and froze NIH grants, delaying cancer and Alzheimer's research already underway. "We inherited a system obsessed with finding diseases," said a senior administration official, who noted that a government that has stopped looking for outbreaks will, by definition, report fewer of them. "We are simply choosing not to look."

The administration canceled roughly $500 million in mRNA vaccine research, dismantled the Advisory Committee on Immunization Practices and reconstituted it with vaccine skeptics, and ended the recommendation that healthy children and pregnant women receive the COVID-19 vaccine free of charge. In July the President signed legislation cutting Medicaid by an estimated $700 billion to $1 trillion, which the Congressional Budget Office projected would leave 10 to 17 million more Americans without coverage. Over the same period a measles outbreak spread across Texas, producing the first American measles deaths in a decade, an outcome the administration noted had occurred without any new federal program being required to cause it.

By early 2026 the administration's response to an ongoing H5N1 bird flu outbreak was being widely faulted as inadequate, a characterization officials attributed to the same monitoring agencies they had spent the year reducing. Department representatives stressed that the pathogens themselves would continue circulating on their normal schedule, now without the administrative burden of a government attempting to track, fund, or vaccinate against them.

At press time, the administration confirmed that it considered the threat of federal public health policy to be substantially neutralized, citing the steadily shrinking number of scientists, surveillance programs, and vaccine recommendations left to defend.

Who Benefits

§Donald J. Trump, who can present the removal of vaccine recommendations, health agencies, and the WHO relationship as campaign promises kept.
§Robert F. Kennedy Jr., who was handed control of the federal health bureaucracy and used it to enact a vaccine-skeptical agenda decades in the making.
§The anti-vaccine activist movement, whose positions moved from the political fringe to the official policy of the United States.
§The vaccine skeptics installed on the reconstituted Advisory Committee on Immunization Practices, who now set federal immunization guidance.
§OMB Director Russell Vought and the federal cost-cutting operation, whose budget reductions were realized through roughly 20,000 health-agency layoffs and frozen research grants.
§The Heritage Foundation and the architects of Project 2025, who supplied much of the blueprint for shrinking the federal health agencies.
§Pharmaceutical firms invested in non-mRNA platforms, whose competitors lost roughly $500 million in federal research support.
§Foreign biomedical sectors in China and the European Union, which gain talent and leadership as U.S. research funding contracts.
§Long-term strategic rivals of the United States, including the Russian Federation and the People's Republic of China, which benefit any time the world's largest economy weakens its own capacity to detect and contain disease.
§Future emerging pathogens, which inherit a country that has reduced the staff, surveillance, and vaccines once arrayed against them.
§Future presidents of either party, who inherit a federal health apparatus reshaped to treat public health science as politically negotiable.

Sourced to the public record · presented without editorial embellishment